Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.

Autor:	Seifert M; Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., Bera SC; Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., van Nies P; Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., Kirchdoerfer RN; Department of Biochemistry and Institute of Molecular Virology, University of Wisconsin-Madison, Madison, United States., Shannon A; Architecture et Fonction des Macromolécules Biologiques, CNRS and Aix-Marseille Université, Marseille, France., Le TT; Architecture et Fonction des Macromolécules Biologiques, CNRS and Aix-Marseille Université, Marseille, France., Meng X; Department of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, United States., Xia H; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, United States., Wood JM; The Ferrier Research Institute, Victoria University of Wellington, Wellington, New Zealand., Harris LD; The Ferrier Research Institute, Victoria University of Wellington, Wellington, New Zealand., Papini FS; Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., Arnold JJ; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, United States., Almo S; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, Institute for Protein Innovation, Boston, United States., Grove TL; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, Institute for Protein Innovation, Boston, United States., Shi PY; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Institute for Human Infections and Immunity, University of Texas Medical Branch, Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, United States., Xiang Y; Department of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, United States., Canard B; Architecture et Fonction des Macromolécules Biologiques, CNRS and Aix-Marseille Université, Marseille, France., Depken M; Department of Bionanoscience, Kavli Institute of Nanoscience, Delft University of Technology, Delft, Netherlands., Cameron CE; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, United States., Dulin D; Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.; Department of Physics and Astronomy, and LaserLaB Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Jazyk:	angličtina
Zdroj:	ELife [Elife] 2021 Oct 07; Vol. 10. Date of Electronic Publication: 2021 Oct 07.
DOI:	10.7554/eLife.70968
Abstrakt:	The absence of 'shovel-ready' anti-coronavirus drugs during vaccine development has exceedingly worsened the SARS-CoV-2 pandemic. Furthermore, new vaccine-resistant variants and coronavirus outbreaks may occur in the near future, and we must be ready to face this possibility. However, efficient antiviral drugs are still lacking to this day, due to our poor understanding of the mode of incorporation and mechanism of action of nucleotides analogs that target the coronavirus polymerase to impair its essential activity. Here, we characterize the impact of remdesivir (RDV, the only FDA-approved anti-coronavirus drug) and other nucleotide analogs (NAs) on RNA synthesis by the coronavirus polymerase using a high-throughput, single-molecule, magnetic-tweezers platform. We reveal that the location of the modification in the ribose or in the base dictates the catalytic pathway(s) used for its incorporation. We show that RDV incorporation does not terminate viral RNA synthesis, but leads the polymerase into backtrack as far as 30 nt, which may appear as termination in traditional ensemble assays. SARS-CoV-2 is able to evade the endogenously synthesized product of the viperin antiviral protein, ddhCTP, though the polymerase incorporates this NA well. This experimental paradigm is essential to the discovery and development of therapeutics targeting viral polymerases. Competing Interests: MS, SB, Pv, RK, AS, TL, XM, HX, JW, LH, FP, JA, SA, TG, PS, YX, BC, MD, CC, DD No competing interests declared (© 2021, Seifert et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu